Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has undergone one of the most profound therapeutic transformations in oncology. Once associated with poor outcomes, it is now a highly curable disease in the early-stage setting, and a substantial proportion of patients with metastatic disease survive beyond 5 years.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Elia Seguí
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) | Nature Communications
|
By Tomás Pascual, Maria Espie Vidal, María Vidal Verified, Juan M. Cejalvo, Estela Vega, Esther Sanfeliu, Guillermo Villacampa, Sergi Ganau, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Elia Seguí, Manel Juan, Patricia Galván, Samyukta Chillara, Patricia Villagrasa, Adam D. Pfefferle, Mafalda Oliveira, Charles M. Perou, Aleix Prat, Fara Brasó-Maristanty, Xavier Gonzàlez-Farré, Constandina E. O’Connell, Juan M. Ferrero-Cafiero
|
Nature
Verified
Abstract This single-arm, phase II, preoperative window-of-opportunity trial (ClinicalTrials.gov Identifier: NCT03802604) investigated the efficacy and safety of talimogene laherparepvec (T-VEC), an oncolytic virus, with atezolizumab, an anti–PD-L1 antibody, in patients with breast cancer and radiologically and pathologically confirmed residual disease prior to surgery.
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
Background After first-line endocrine therapy (ET) plus CDK4/6 inhibitor (CDK4.6i) in estrogen receptor–positive/HER2-negative (ER+/HER2–) metastatic breast cancer, tumors develop resistance to intrinsic alterations in the cell cycle or PI3K/AKT/mTOR pathways or to acquired ESR1 mutation that emerges in up to 50% of patients.
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 15 July 2024 / Approved: 15 July 2024 / Online: 16 July 2024 (00:25:58 CEST) Seguí, E.; Torres Canizales, J.; Auclin, E.; Casadevall, D.; Peiro Carmona, S.; Aguilar-Company, J.; García de Herreros, M.; Laguna, J. C.; Gorria, T.; Rodríguez, M.; Gonzalez, A.; Epaillard, N.; Gavira, J.; Bolaño, V.; Tapia, J.
Successful management of refractory immune-mediated enterocolitis with cyclosporine
David Pesántez Elia Seguí Ingrid Ordás Ingrid Ordás Affiliations IBD Unit, Gastroenterology Department, Hospital Clínic of Barcelona, CIBERehd, Barcelona, SpainInstitut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain Search for articles by this author Marga Viladot Ana Arance Ana Arance Correspondence Corresponding author: Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Elia
Contact Elia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack